We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
15 Nov 2021 - 18 Nov 2021

Ultrasound Stimulation Reduces COVID-19-Related Inflammation and Decreases Length of Hospital Stays

By MedImaging International staff writers
Posted on 14 May 2021
Print article
Image: Ultrasound Stimulation Reduces COVID-19-Related Inflammation and Decreases Length of Hospital Stays (Photo courtesy of SecondWave Systems)
Image: Ultrasound Stimulation Reduces COVID-19-Related Inflammation and Decreases Length of Hospital Stays (Photo courtesy of SecondWave Systems)
Researchers have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

The two- to three-month study, called Ultrasound Neural and Immunomodulation Treatment Evaluation Study for COVID-19 or UNITE Study, by researchers at University of California San Diego School of Medicine (San Diego, CA, USA), will recruit 40 patients with severe COVID-19 symptoms. Half of the patients in the trial will be given ultrasound treatment daily for up to seven days, in addition to receiving anti-inflammatory drugs, such as remdesivir and dexamethasone, which are currently part of standard medical care. The other half - the control group - will receive only standard medical care.

In earlier rodent studies, stimulating the spleen with a non-invasive ultrasound device was shown to reduce inflammation. Researchers have also demonstrated the anti-inflammatory value of spleen stimulation in healthy human subjects and in human patients with rheumatoid arthritis (RA). Both RA and COVID-19 patients can suffer from a hyperinflammatory response driven by over-production of cytokines - proteins that signal and spur an inflammatory immune response. The resulting “cytokine storm” in COVID-19 patients can lead to acute respiratory distress syndrome, known as ARDS, which can be fatal.

A July 2020 study had demonstrated the effects of splenic stimulation in RA and healthy patients, and its potential in COVID-19 patients. Prior studies have also shown that electrical stimulation of the vagus nerve, which runs from the brain to the gut, using a cervical implant, reduces inflammation. Stimulating the spleen may activate the same anti-inflammatory pathways. The clinical trial will use an investigational device strategically placed on patients’ skin that generates low-intensity, focused ultrasound waves targeting the spleen. Treatment occurs daily for approximately 18 minutes for up to seven days.

“It’s a pilot study to evaluate whether ultrasound stimulation focused on the spleen can reduce inflammatory biomarkers in hospital patients infected with SARS-CoV-2,” said Imanuel Lerman, MD, associate professor of anesthesiology at UC San Diego School of Medicine and an affiliate of Qualcomm Institute at UC San Diego, where his lab is based. “This will allow us to determine whether treating patients this way can really affect clinical outcomes in COVID-19 infections.”

Related Links:
University of California San Diego School of Medicine

Print article



view channel
Image: Mindray TE7 Max Ultrasound System (Photo courtesy of Mindray)

Mindray's New TE7 Max Ultrasound System Expands Possibilities for Point of Care

Mindray North America (Mahwah, NJ, USA) has launched its new TE7 Max ultrasound system that maximizes the potential of ultrasound in the Point of Care (POC) market. The TE7 Max has a 21.... Read more

Imaging IT

view channel

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel

Intelerad Acquires Cloud Specialist Ambra Health to Form Global Enterprise Imaging Giant

Intelerad Medical Systems (Raleigh, NC, USA), a leading provider of medical image management solutions, has acquired Ambra Health (New York, NY, USA), maker of a leading cloud-based medical image management... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.